How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Has all of the relevant evidence been taken into account?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about dupilumab

Marketing authorisation indication

2.1

Dupilumab (Dupixent, Sanofi) is indicated in 'adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate'.

Price

2.3

The list price of dupilumab is £1,264.89 for a 2‑pack of 300 mg per 2 ml pre-filled pens or pre-filled syringes. (excluding VAT; BNF online accessed March 2025).

2.4

The company has a commercial arrangement. This makes dupilumab available to the NHS with a discount and it would have also applied to this indication if dupilumab had been recommended. The size of the discount is commercial in confidence.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Sanofi will be included here when guidance is published.